MUNI | CREATIC

What MUNI | CREATIC does

CREATIC (Central European Advanced Therapy and Immunotherapy Centre) is a non-profit research centre of excellence operating under Masaryk University in Brno, Czech Republic. Founded in 2022 through a Horizon Europe Teaming for Excellence grant of EUR 15 million over six years, the centre focuses on Advanced Therapy Medicinal Products (ATMPs) — including cell and gene therapies — for patients with rare diseases, paediatric patients with high-risk tumours, and adult cancer patients suitable for ATMP treatment. CREATIC operates the CREPROFA GMP-compliant manufacturing facility for clinical production of mesenchymal cell-based products and dendritic cell anti-cancer immunotherapies, and has secured the first hospital exemption for an ATMP in the Czech Republic. The centre also runs the BabyFox rapid whole-genome sequencing project led by Prof. Ondřej Slabý for paediatric genetic diagnostics.

The centre is organised around seven research programmes combining science, technology and medicine (STM) with social sciences and humanities (SSH) disciplines, and offers a comprehensive services portfolio for clinical trial execution and ATMP development: project management, medical writing, regulatory affairs, pharmacovigilance, pharmacoeconomics, data management and biostatistics, monitoring, and grant advisory services. Educational offerings include eight micro-credential ATMP courses delivered via Moodle (covering GMP, immunology, oncology, immunotherapy, and EU regulatory frameworks) and the LabtoP Talks expert webinar series. CREATIC draws on foundational expertise from the Czech Clinical Research Infrastructure Network (CZECRIN) and strategic European partnerships with Fraunhofer Institute for Cell Therapy and Immunology IZI (Leipzig), Leipzig University, and the University of Copenhagen.

CREATIC operates as a publicly grant-funded research infrastructure rather than a revenue-generating commercial enterprise, with no disclosed pricing, ARR, or commercial customers. Its 15 staff serve a diversified stakeholder mix of clinical trial sponsors, academic researchers, healthcare professionals, students, and patients across the Czech Republic, Germany, and Denmark. Revenue is institutional in nature, sourced from the European Union's Horizon Europe programme and complementary TEAMING-CZ I (P JAC) investment support, with no private equity, venture capital, or public ownership involvement.

Name

MUNI | CREATIC

Legal name

CREATIC - Central European Advanced Therapy and Immunotherapy Centre

Website

https://creatic.muni.cz

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

CREATIC is a non-profit research centre of excellence under Masaryk University in Brno, Czech Republic, developing Advanced Therapy Medicinal Products (cell and gene therapies) for rare diseases, paediatric oncology, and adult cancer patients, funded by a EUR 15 million Horizon Europe grant.

Ownership category

akta.pro rank

Product category

ATMP and Cell/Gene Therapy Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Educational Support Services (61171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Advanced therapy medicinal products
• Cell and gene therapy
• Clinical trial services
• GMP pharmaceutical manufacturing
• Biomedical education programs

Headquarters

HQ city

Brno

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

CREATIC is a research Centre of Excellence that provides comprehensive clinical trial services and GMP-compliant manufacturing for Advanced Therapy Medicinal Products (ATMPs) — including cell and gene therapies — targeting rare diseases, paediatric oncology, and adult cancer patients. Its offering spans clinical trial consultancy, regulatory affairs, pharmacovigilance, pharmacoeconomics, data management/biostatistics, ATMP manufacturing via the CREPROFA facility, and interdisciplinary micro-credential education delivered through partner universities.

Product overview

CREATIC (Central European Advanced Therapy and Immunotherapy Centre) is a research centre of excellence focused on Advanced Therapy Medicinal Products (ATMPs) for rare diseases, paediatric oncology, and adult cancer patients. The centre operates under Masaryk University with strategic partnerships with Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig University, and University of Copenhagen. CREATIC offers a comprehensive portfolio of services encompassing clinical trials (project management, medical writing, quality control, monitoring), regulatory affairs, pharmacovigilance, pharmacoeconomics, and data management/biostatistics. The centre operates the GMP-compliant CREPROFA manufacturing facility for ATMP development. Educational offerings include eight micro-credential courses delivered via Moodle covering GMP, immunology, oncology, and regulatory topics, plus the LabtoP Talks webinar series. CREATIC builds upon the Czech Clinical Research Infrastructure Network (CZECRIN) and has obtained the first hospital exemption for an ATMP in the Czech Republic.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Services Comprehensive consultancy for clinical trials in ATMP development, including project management, medical writing, scientific advice, quality control/assurance, and monitoring services for clinical trial sponsors and academic researchers developing advanced therapies.
• Regulatory Affairs Expert guidance on regulatory requirements and strategies for ATMP development and clinical trials in the European Union, supporting clinical trial sponsors navigating complex cell and gene therapy approval pathways.
• Pharmacovigilance Safety monitoring and pharmacovigilance services for clinical trials and marketed advanced therapy medicinal products, supporting sponsors in meeting EU post-marketing and trial safety obligations.
• Pharmacoeconomics Economic assessment and evaluation services for healthcare interventions and medicinal products, supporting clinical trial sponsors and health system stakeholders in assessing value of advanced therapies.
• Data Management & Biostatistics Clinical data management and statistical analysis services for clinical trials and research studies in advanced therapy medicinal products, serving sponsors and academic research groups.
• Advice on Grant and Project Calls Consultancy and guidance on research grant applications and project funding opportunities for academic and clinical research groups seeking ATMP and clinical research funding.
• CREPROFA GMP Manufacturing Facility Good Manufacturing Practice (GMP) compliant manufacturing centre enabling integrated research, development, and clinical production of advanced therapy medicinal products, producing mesenchymal cell-based products and anti-cancer dendritic cell immunotherapies for clinical trial sponsors.
• Centre for Precision Medicine Clinical centre connecting advanced diagnostics, clinical expertise, and individualized approaches to patient care, supporting precision medicine applications for patients with rare diseases and genetic conditions.
• CREATIC Micro-Certified Courses Series of eight micro-certified online courses covering technological and manufacturing principles, GMP automation, immunology, oncology, immunotherapy, lab-to-patient pathways, and EU ATMP regulatory frameworks, delivered via Moodle to healthcare professionals and biomedical learners.
• CREATIC LabtoP Talks Webinar Series Expert webinar series addressing ATMP lifecycle topics including regulatory frameworks, patient pathways, genomics, cell engineering, intellectual property, hospital exemption, and clinical trials, organized with Fraunhofer IZI and University of Copenhagen for the professional and expert public.

Quantifiable outcome

• 17,451 patients accessed innovative treatment in Czech Republic in 2025 alone through clinical trials
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Fraunhofer Institute for Cell Therapy and Immunology IZIcoreStrategic or Co-development Partner · 1 September 2022Strategic partnership with Fraunhofer IZI (Leipzig, Germany) as part of Horizon Europe Teaming for Excellence project. Fraunhofer IZI is a leading institution in cell therapy and immunology research, contributing expertise to establish the ATMP Centre of Excellence at Masaryk University.
• Leipzig UniversitycoreStrategic or Co-development Partner · 1 September 2022Partnership with Leipzig University as part of the Horizon Europe Teaming for Excellence initiative. Contributes to the 7 research programmes combining STM and SSH disciplines and develops educational content including micro-certified courses.
• University of CopenhagencoreStrategic or Co-development Partner · 1 September 2022Strategic partnership with University of Copenhagen as part of the Horizon Europe Teaming for Excellence project. Contributes to ATMP research and educational programs including the LabtoP Talks webinar series.
• CZECRIN (Czech Clinical Research Infrastructure Network)coreStrategic or Co-development Partner · 1 September 2022CREATIC builds on decades of expertise in the research, development and manufacturing of pharmaceuticals at the Large Research Infrastructure CZECRIN. CZECRIN links academia, clinical centres, and expert teams and helps build conditions for trials meeting international standards.
• Masaryk UniversitycoreOthersCREATIC is an initiative of Masaryk University, serving as the central coordinating institution for the Centre of Excellence.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Fraunhofer Institute for Cell Therapy and Immunology (IZI): Fraunhofer IZI is a direct partner and the closest functional peer to CREATIC, performing contract research, GMP manufacturing, and translational work in cell therapy, gene therapy, and immunology across rare disease and oncology—often for the same sponsors and indications.
• Leipzig University – Centre for Biotechnology and Biomedicine: Leipzig University is both a strategic partner and a direct peer institution combining academic ATMP research, clinical trial infrastructure, and educational offerings—a useful structural analogue to CREATIC within the German partner network.
• Cell and Gene Therapy Catapult: UK-based not-for-profit Catapult is the closest mission-equivalent: an ATMP-focused centre of excellence offering GMP manufacturing, clinical trial support, regulatory, and skills training, funded largely by government grants—an almost exact analogue in operating model.

Broad incumbents

• Medpace: Medpace is a mid-to-large global CRO with strong biotech sponsor franchise; it is a relevant incumbent competitor for the full-service clinical trial mandates CREATIC targets, particularly in oncology and rare disease.
• IQVIA: IQVIA is the world's largest CRO with deep presence across clinical operations, biostatistics, regulatory, and pharmacovigilance; it competes with CREATIC for ATMP and rare-disease trial mandates as part of a much broader portfolio.
• Charles River Laboratories: Charles River combines research models, discovery, safety, and CDMO services including cell and gene therapy manufacturing; it overlaps with CREATIC's pre-clinical and ATMP manufacturing capabilities as an established industry incumbent.
• ICON plc: ICON is a global CRO covering project management, regulatory, biostatistics, and pharmacovigilance; it absorbs ATMP and rare-disease clinical work at scale, providing the standard incumbent benchmark against which CREATIC's full-service offerings compete.
• Lonza: Lonza is a leading global CDMO with dedicated cell and gene therapy manufacturing capacity; it competes with CREPROFA for ATMP manufacturing contracts and represents the dominant commercial benchmark in the ATMP CDMO space.
• Eurofins Scientific: Eurofins is a global life-sciences testing and contract research group with central laboratory and biopharma services; it overlaps with CREATIC's central lab, genomic (BabyFox), and clinical trial testing capabilities at far larger scale.

Emerging players

• Miltenyi Biotec: Miltenyi Biotec provides cell and gene therapy manufacturing platforms, reagents, and services along with clinical-grade cell processing—a partial-overlap ATMP peer that competes for cell-therapy manufacturing and process development work.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CreaticMuni
• LinkedInlinkedin.com/company/muni-creatic
• Instagraminstagram.com/muni_creatic

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MUNI | CREATIC